February 10, 2020 / 12:38 PM / 18 days ago

Biohaven anxiety treatment fails in late-stage study

Feb 10 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd on Monday said its treatment for anxiety disorder failed to meet the main goal in a late-stage study, sending its shares down 25%.

In the study, patients receiving the experimental drug, troriluzole, twice everyday did not show improvement in anxiety symptoms, compared to a placebo. (Reporting By Mrinalika Roy in Bengaluru Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below